WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H540259
CAS#: 74103-07-4
Description: Ketorolac tromethamine is an NSAID and COX-1/2 inhibitor. It also prevents spinal injury-induced increase of PAR1 and decreases expression of PDE4D.
Hodoodo Cat#: H540259
Name: Ketorolac tromethamine
CAS#: 74103-07-4
Chemical Formula: C26H28FN3O9
Exact Mass: 376.16
Molecular Weight: 376.409
Elemental Analysis: C, 57.25; H, 5.17; F, 3.48; N, 7.70; O, 26.40
Related CAS #: 74103-07-4 66635-93-6 (R-isomer)
Synonym: Acular; Godek; Sprix; Syntex; Toradol; Ketorolac tromethamine
IUPAC/Chemical Name: 2-amino-2-(hydroxymethyl)propane-1,3-diol 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate
InChi Key: BWHLPLXXIDYSNW-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2
SMILES Code: O=C(C1C2=CC=C(C(C3=CC=CC=C3)=O)N2CC1)O.OCC(CO)(N)CO
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 376.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Li C, Li C, Liu Z, Li Q, Yan X, Liu Y, Lu W. Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. Int J Pharm. 2014 Oct 20;474(1-2):123-33. doi: 10.1016/j.ijpharm.2014.08.023. Epub 2014 Aug 17. PubMed PMID: 25138250.
2: Vadivelu N, Gowda AM, Urman RD, Jolly S, Kodumudi V, Maria M, Taylor R Jr, Pergolizzi JV Jr. Ketorolac tromethamine - routes and clinical implications. Pain Pract. 2015 Feb;15(2):175-93. doi: 10.1111/papr.12198. Epub 2014 Apr 16. Review. PubMed PMID: 24738596.
3: Ticly FG, Lira RP, Zanetti FR, Machado MC, Rodrigues GB, Arieta CE. Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. J Ocul Pharmacol Ther. 2014 Aug;30(6):495-501. doi: 10.1089/jop.2013.0214. Epub 2014 Apr 15. PubMed PMID: 24735005.
4: Beitzel K, McCarthy MB, Cote MP, Apostolakos J, Russell RP, Bradley J, ElAttrache NS, Romeo AA, Arciero RA, Mazzocca AD. The effect of ketorolac tromethamine, methylprednisolone, and platelet-rich plasma on human chondrocyte and tenocyte viability. Arthroscopy. 2013 Jul;29(7):1164-74. doi: 10.1016/j.arthro.2013.04.006. PubMed PMID: 23809450.
5: Lyra AF, Bastos LC, Lima RC, Maranhão Lde V, Arantes TE. Artificial tears alone versus 0.45% ketorolac tromethamine with artificial tears for the treatment of acute viral conjunctivitis. Arq Bras Oftalmol. 2014 Apr;77(2):99-102. PubMed PMID: 25076474.
6: Mettu SR, Veerareddy PR. Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. Drug Res (Stuttg). 2013 Nov;63(11):586-90. doi: 10.1055/s-0033-1348258. Epub 2013 Jun 18. PubMed PMID: 23780501.
7: Kalariya PD, Raju B, Borkar RM, Namdev D, Gananadhamu S, Nandekar PP, Sangamwar AT, Srinivas R. Characterization of forced degradation products of ketorolac tromethamine using LC/ESI/Q/TOF/MS/MS and in silico toxicity prediction. J Mass Spectrom. 2014 May;49(5):380-91. doi: 10.1002/jms.3351. PubMed PMID: 24809899.
8: Li X, Du L, Chen X, Ge P, Wang Y, Fu Y, Sun H, Jiang Q, Jin Y. Nasal delivery of analgesic ketorolac tromethamine thermo- and ion-sensitive in situ hydrogels. Int J Pharm. 2015 Jul 15;489(1-2):252-60. doi: 10.1016/j.ijpharm.2015.05.009. Epub 2015 May 6. PubMed PMID: 25957699.
9: Bullingham R, Juan A. Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. Drugs Aging. 2012 Nov;29(11):899-904. doi: 10.1007/s40266-012-0023-2. PubMed PMID: 23143939.
10: Stephens DM, Richards BG, Schleicher WF, Zins JE, Langstein HN. Is ketorolac safe to use in plastic surgery? A critical review. Aesthet Surg J. 2015 May;35(4):462-6. doi: 10.1093/asj/sjv005. Epub 2015 Mar 29. Review. PubMed PMID: 25825424.
11: Vemula SK. Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. Int J Pharm. 2015 Aug 1;491(1-2):35-41. doi: 10.1016/j.ijpharm.2015.06.007. Epub 2015 Jun 6. PubMed PMID: 26056929.
12: Vemula SK, Veerareddy PR. Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. Expert Opin Drug Deliv. 2013 Jan;10(1):33-45. doi: 10.1517/17425247.2013.743528. Epub 2012 Nov 30. PubMed PMID: 23199134.
13: Kulo A, Hendrickx S, de Hoon J, Mulabegovic N, van Calsteren K, Verbesselt R, Allegaert K. The impact of pregnancy on urinary ketorolac metabolites after single intravenous bolus. Eur J Drug Metab Pharmacokinet. 2013 Mar;38(1):1-4. doi: 10.1007/s13318-012-0108-7. Epub 2012 Nov 21. PubMed PMID: 23179562.
14: Mathew ST, Subbiah GD, Vasantha PV, Balan V. Characterization and pharmacokinetic evaluation of gamma sterilized ketorolac tromethamine loaded albumin microspheres for intramuscular administration. Curr Drug Deliv. 2013 Apr;10(2):158-66. PubMed PMID: 23157434.
15: Schoenberger SD, Kim SJ, Sheng J, Calcutt MW. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. JAMA Ophthalmol. 2014 Feb;132(2):150-4. doi: 10.1001/jamaophthalmol.2013.5692. PubMed PMID: 24264034.
16: Bacon R, Newman S, Rankin L, Pitcairn G, Whiting R. Pulmonary and nasal deposition of ketorolac tromethamine solution (SPRIX) following intranasal administration. Int J Pharm. 2012 Jul 15;431(1-2):39-44. doi: 10.1016/j.ijpharm.2012.04.023. Epub 2012 Apr 13. PubMed PMID: 22525081.
17: Ramakrishnan S, Baskaran P, Talwar B, Venkatesh R. Prospective, Randomized Study Comparing the Effect of 0.1% Nepafenac and 0.4% Ketorolac Tromethamine on Macular Thickness in Cataract Surgery Patients With Low Risk for Cystoid Macular Edema. Asia Pac J Ophthalmol (Phila). 2015 Jul-Aug;4(4):216-20. doi: 10.1097/APO.0000000000000089. PubMed PMID: 26225780.
18: Drover DR, Hammer GB, Anderson BJ. The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. Anesth Analg. 2012 Jun;114(6):1270-6. doi: 10.1213/ANE.0b013e31824f92c2. Epub 2012 Mar 30. PubMed PMID: 22467894.
19: Guo Y, Kenney SR, Cook L, Adams SF, Rutledge T, Romero E, Oprea TI, Sklar LA, Bedrick E, Wiggins CL, Kang H, Lomo L, Muller CY, Wandinger-Ness A, Hudson LG. A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients. Clin Cancer Res. 2015 Nov 15;21(22):5064-72. doi: 10.1158/1078-0432.CCR-15-0461. Epub 2015 Jun 12. PubMed PMID: 26071482; PubMed Central PMCID: PMC4644688.
20: Shafiee A, Bowman LM, Hou E, Hosseini K. Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. J Ocul Pharmacol Ther. 2013 Nov;29(9):812-6. doi: 10.1089/jop.2013.0016. Epub 2013 Aug 31. PubMed PMID: 23992042.
